藥物成份

共有 21645 個藥物成份

Pilocarpine Hydrochloride contains NLT 99% and NMT101% of C11H16N2O2‧HCl, calculated on the dried basis.

• 關聯藥證數量: 1

Pilocarpine Hydrochloride contains not less than 99.0% and not more than 101.0% of C11H16N2O2•HCl calculated on dried substance.

• 關聯藥證數量: 1

Pinaverium Bromide contains not less than 99.0% and not more than 101.0% of C26H41Br2NO4, calculated on dried basis.

• 關聯藥證數量: 1

Pinaverium Bromide contains not less than 99.0% and not more than 101.0% of C26H41NO4Br2, calculated with reference to the anhydrous and solvent-free substance.

• 關聯藥證數量: 1

Pioglitazone Hydrochloride contains NLT 98.0% and NMT 102.0% of C19H20N2O3S˙HCl, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Pioglitazone Hydrochloride contains NLT 98.0% and NMT 102.0% of C19H20N2O3S．HCl, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Pioglitazone Hydrochloride contains not less than 98.0% and not more than 102.0% of C19H20N2O3S‧HCl, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Pioglitazone Hydrochloride contains not less than 99.0% and not more than 101.0% of C19H20N2O3S.HCl, calculated on dried basis.

• 關聯藥證數量: 1

Pioglitazone Hydrochloride, when dried,contains between 98% and 102% of C19H20N2O3S .HCl

• 關聯藥證數量: 1

Piolitazone Hydrochloride contains not less than 98.0% and not more than 102% of C19H20N2O3S？HCl, calculated on the dried basis.

• 關聯藥證數量: 1

Pipemidic Acid Hydrate

• 關聯藥證數量: 1

Pipemidic Acid, when dried,contains not less than 98.5% of C14H17N5O3

• 關聯藥證數量: 1

Piperacillin Sodium Sterile has a potency equivalent to not less than 863μg and not more than 1007μg of piperacillin (C23H27N5O7S) per mg, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Piperacillin Sodium and Tazobactam Sodium(8:1) contain： - Not less than 80.7% and not more than 86.7% of piperacillin, calculated on the dried basis. - Not less than 9.8% and not more than 10.8% of tazobactam, calculated on the dried basis. - Not less than 84.1% and not more than 90.4% of piperacillin sodium, calculated on the dried basis. - Not less than 10.5% and not more than 11.6% of tazobactam sodium, calculated on the dried basis.

• 關聯藥證數量: 1

Piperacillin Sodium has a potency equivalent to not less than 863 μg and not more than 1007 μg of piperacillin (C23H27N5O7S) per mg, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Piperacillin sodium as equivalent to Piperacillin 2g, 4g\nTazobactam sodium as equivalent to Tazobactam 0.25g, 0.5g

• 關聯藥證數量: 1

Pipes Buffer 80 mmol/l,pH6.8\n4-Aminoantipyrine 0.25 mmol/l\nPhenol 6 mmol/l\nPeroxidase(E.C.1.11.1.7,Horse Radish,+25℃) ≧0.5 U/ml\nCholesterol esterase(E.C.3.1.1.13. Pseudomonas,37℃) ≧0.2 U/ml\nCholesterol oxidase(E.C.1.1.3.6 Nocardia, 37℃) ≧0.10 U/ml\n

• 關聯藥證數量: 1

Pipes buffer 50mmol/l\np-Chlorophenole 2 mmol/l\nLipoprotein Lipase 150000 U/l\nGlycerokinase 800 U/l\nGlycerol-3-P-oxidase 4000 U/l\nPeroxidase 440 U/l\n4-Aminoantipyrine 0.7 mmol/l\nATP 0.3 mmol/l\nMg2+ 40 mmol/l\nNa-cholat 0.20 mmol/l\nPotassium-Hexacyanoferrat(II) 1 μmol/l

• 關聯藥證數量: 1

Pipes buffer：90 mmol/l\nPhenol：26 mmol/l\nCholesterol Oxidase：200 U/l\nCholesterol Esterase：300 U/l\nPeroxidase：1250 U/l\n4-Aminoantipyrine：0.4 mmol/l\n

• 關聯藥證數量: 1

Pipoxolan Hydrochloride contains NLT 98.0% and NMT 102.0% of C22H26ClNO3, calculated on the dried basis.

• 關聯藥證數量: 1

Piracetam contains not less than 98% and not more than 102% of C6H10N2O2,calculated with reference to the dried substance.

• 關聯藥證數量: 1

Piracetam contains not less than 98.0 and not more than 102% of C6H10N2O2,calculated on the dried substance.

• 關聯藥證數量: 1

Piracetam contains not less than 98.0% and not more than 102.0% of C6H10N2O2

• 關聯藥證數量: 1

Piracetam contains not less than 98.0% and not more than 102.0% of C6H10N2O2 calculated on the dried substance.

• 關聯藥證數量: 1

Piracetam contains not less than 98.0% and not more than 102.0% of C6H10N2O2, calculated on dried basis.

• 關聯藥證數量: 1

Piracetam contains not less than 98.0% and not more than 102.0% of C6H10N2O2, calculated on the dried substance.

• 關聯藥證數量: 1

Pirfenidone

• 關聯藥證數量: 1

Pirfenidone contains not less than 98.0 % and not more than 102.0% of C12H11NO, calculated on the dried substance.

• 關聯藥證數量: 1

Pirfenidone contains not less than 98.0% and not more than 102.0% of C12H11NO, calculated on dried substance.

• 關聯藥證數量: 1

Pirfenidone contains not less than 98.0% and not more than 102.0% of C12H11NO, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Piroxicam contains not less than 97.0% and not more than 103.0% of C15H13N3O4S, calculated on the dried basis.

• 關聯藥證數量: 1

Piroxicam contains not less than 97.0% and not more than 103.0% of C15H13N3O4S.

• 關聯藥證數量: 1

Piroxicam contains not less than 98.5% not more than the equivalent of 101.0% of C15H13N3O4S, calculated with reference to the dried substance.

• 關聯藥證數量: 1

Pitavastatin Calcium Not less than 98.0% and not more than 102.0% w/w.

• 關聯藥證數量: 1

Pitavastatin Calcium (Hydrate) contains not less than 98.0% and not more than 102.0% of (C25H23 FNO4)2Ca, calculated on the anhydrous substance.

• 關聯藥證數量: 1

Pitavastatin Calcium (pentahydrate) contains not less than 98.0% and not more than 102.0% of (C25H23FNO4)2Ca・5H2O, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Pitavastatin Calcium Hydrate (Pentahydrate) contains not less than 98.0% and not more than 102.0% of Pitavastatin Calcium (C50H46CaF2N2O8), calculated on the anhydrous basis.

• 關聯藥證數量: 1

Pitavastatin Calcium Hydrate 98.0%~102.0%(as anhydrous basis)

• 關聯藥證數量: 1

Pitavastatin Calcium Hydrate contains not less than 98.0% and not more than 102.0% of pitavastatin calcium (C50H46CaF2N2O8), calculated on the anhydrous basis.

• 關聯藥證數量: 1

Pitavastatin Calcium contains 98.0% ~ 102.0% of C50H46F2N2O8Ca calculated on anhydrous basis.

• 關聯藥證數量: 1

Pitavastatin Calcium contains not less than 98.0% and not more than 101.0% of (C25H23FNO4)2‧Ca, calculated on the anhydrous substance.

• 關聯藥證數量: 1

Pitavastatin calcium hydrate contains not less than 98.0% and not more than 102.0% of C50H46CaF2N2O8, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Plasma N品管液是從健康的捐血者所取得的集合血漿. Plasma N品管液是用高純度的HEPES緩衝溶液(12g/L)加以保存並冷凍乾燥，所以很穩定. 但為避免因接觸而活化凝血系統，本包裝使用矽化物處理過的瓶子封裝. 另外，Plasma N品管液並未添加防腐劑。

• 關聯藥證數量: 1

Plasmin (human), lyophilized; concentration in the working solution: 0.1 CTA U/mLPlasmin Substrate, lyophilized; concentration in the working solution: D-Norvalyl-cyclohexylala-nyl-lysyl-p-nitroanilide (HD-Nva-CHA-Lys-CHA-pNA) 3 mmol/LBuffer solution: KH2PO4(100 mmol/L), NaCl (9 g/L), glycerol (250 g/L), pH7.5

• 關聯藥證數量: 1

Plastic Bag

• 關聯藥證數量: 1

Plastic Forceps\nPlastic Forceps, 2 per package.

• 關聯藥證數量: 1

Plastic manufacured vacuum blood collection tubes, silicone coated.

• 關聯藥證數量: 1

Plastinex, 20 x 4.0 ml

• 關聯藥證數量: 1

Plate: 96det. Microwell plate, 12 microwell strips in strip holder; coated with monoclonal antibodies against astroviruses\nDiluent: 100mL. Sample-dilution buffer, protein-buffered NaCl solution; contains 0.1% Kathon\nWash: 100mL. Wash buffer, phosphate-buffered NaCl solution (10-fold concentrate); contains 0.1% Thimerosal\nControl+: 1.8mL. Inactivated astroviruses\nConjugate: 10mL. Peroxidase-conjugated antibody in stabilized protein solution; contains 0.1% Kathon\nSubstrate: 10mL. Urea peroxide/TMB\nStop: 6mL. Stop reagent. 1N sulphuric acid

• 關聯藥證數量: 1

Plate： 12 microwell strips（can be divided）in the strip holder, coated with EBNA-1\nSeroPP：Sample buffer, phosphate-buffered NaCI solution；coloured yellow；contains 0.01% thimerosal and 0.05% tween 20\nSeroWP：Wash buffer, 10-fold concentrate；tris-buffered NaCI solusion；contains 0.2% bronidox-L and 0.5% tween 20\nControl IgG＋：Standard control IgG, diluted human serum；coloured green；contains 0.01% thimerosal and 0.05% tween 20\nControl IgG-：Negative control IgG, diluted human serum；contains 0.01% thimerosal and 0.05% tween 20 \nSeroG LD：Anti-human IgG conjugate（goat）, peroxidase conjugated antibodies in stabilised protein solution；contains 10 ppm proclin, 0.01 % methylisothiazolinone, 0.01 % bromonitrodioxane. \nSeroSC：Substrate；H2O2/tetramethylbenzidine\nSeroStop：Stop reagent0.5 M sulphuric acid

• 關聯藥證數量: 1

Plectranthus amboinicus extract fraction 4 contains 0.159% ~ 0.265% of salvigenin.±

• 關聯藥證數量: 1

Pneumococcal antisera are raised in rabbits. Each vial contains 1ml antiserum preserved with 15 mM sodium azide.

• 關聯藥證數量: 1

Pneumoslide Streptococcus pneumoniae Antibody-Coated Latex Bead Suspension (2.5 mL) is a 1% suspension of latex beads with rabbit antibody specific for S. pneumoniae capsular antigens in glycine buffer. \nPneumoslide Polyvalent Positive Control. \nPneumoslide Latex Negative Control.

• 關聯藥證數量: 1

Policresulen 50% solution contains not less than 45% w/w and not more than 55% w/w of C23H24O12S3.

• 關聯藥證數量: 1

Policresulen 50% solution contains not less than 45.0% w/w and not more than 55.0% of C23H24O12S3

• 關聯藥證數量: 1

Policresulen solution contains not less than 45.5% w/w and not more than 54.5% w/w of C23H24O12S3.

• 關聯藥證數量: 1

Poloxame

• 關聯藥證數量: 1

Poloxamer

• 關聯藥證數量: 1

Poloxamer 407

• 關聯藥證數量: 1

Polyaminopropyl Biguanide (20%)

• 關聯藥證數量: 1

Polyaminopropyl Biguanide Solution 20% w/w (PAPB Hydrochloride 20% w/w).....0.00779＊\nBoric Acid.....6.4\nSodium Borate.....0.9\nEdetate Disodium.....1.1＊＊\nSodium Chloride.....4.9\nPoloxamine 1107.....10.0\nHydroxyalkylPhosphonate (30%).....1.0\nHydrochloric Acid, 1N.....As needed (pH)\nSodium Hydroxide, 1N.....As needed (pH)\nPurified Water, 1N.....1.0\n＊Includes a 18% manufacturing overage\n＊＊Includes a 10% manufacturing overage\n以下空白

• 關聯藥證數量: 1

Polyethylene Glycol 400

• 關聯藥證數量: 1

Polyethylene Glycol Mono-p-isooctylphenyl Ether\n(Triton X-100)\nSodium azide\nSodium phosphate tribasic dodecahydrate

• 關聯藥證數量: 1

Polyhexamethyl Biguanide Solution 20% w/w（PAPB Hydrochloride20% w/w)..........0.0047mg\nBoric Acid..........................6.4mg\nEdetate Disodium...............1.1mg\nSodium Chloride.................4.9mg\nPoloxamine........................10.0mg\nHydrochloric Acide1N..........As needed(pH)\nSodium Hydroxide 1N..........As needed(pH)\nPurified Water 1N...........qs.to1.0ml\n以下空白\n\n

• 關聯藥證數量: 1

Polyhexamethylene Biguanide (PHMB)

• 關聯藥證數量: 1

Polyhexamethylene Biguanide Hydrochloride Solution 20% (Cosmocil CQ) (PHMB)

• 關聯藥證數量: 1

Polyhexamethylene Biguanide Hydrochloride Solution 20% (Cosmocil CQ) (PHMB)

• 關聯藥證數量: 1

Polyhexamethylene biguanide (PHMB).....0.0015 mg/ml\nEdetate. 2Na.....0.5 mg/ml\nPoloxamer.....0.5 mg/ml \nHydroxypropyl Methylcellulose.....1.2 mg/ml\nBoric acid.....8.233 mg/ml\nBorax......0.9 mg/ml\nSodium chloride.....4.56 mg/ml\nWater for purification.....q.s. to 1 ml\n以下空白

• 關聯藥證數量: 1

Polyhexamethylene biguanide (PHMB).....0.0018 mg/ml;\nEdetate. 2Na.....0.5 mg/ml;\nPoloxamer.....1.0 mg/ml;\nHPMC.....1.2 mg/ml;\nGlycerine.....2.0 mg/ml;\nMenthol.....0.004 mg/ml;\nBoric acid.....6.4 mg/ml;\nBorax.....0.9 mg/ml;\nSodium chloride.....5.0 mg/ml;\nPurified Water.....q.s. to 1 ml \n以下空白

• 關聯藥證數量: 1

Polyhexamethylene biguanide (PHMB).....0.0018 mg/ml\nEdetate. 2Na.....0.5 mg/ml\nPoloxamer.....2.0 mg/ml \nHydroxypropyl Methylcellulose.....0.6 mg/ml\nBoric acid.....6.4 mg/ml\nBorax.....0.9 mg/ml\nSodium chloride.....5.5 mg/ml\nWater for purification.....q.s. to 1 ml \n以下空白

• 關聯藥證數量: 1

Polyhexamethylene biguanide (PHMB).....0.0018 mg/ml\nEdetate. 2Na.....0.5 mg/ml\nPoloxamer.....2.0 mg/ml \nHydroxypropyl Methylcellulose.....1.2 mg/ml\nGlycerine.....2.0 mg/ml\nBoric acid.....6.4 mg/ml\nBorax.....0.9 mg/ml\nSodium chloride.....4.6 mg/ml\nPotassium chloride.....0.4 mg/ml\nWater for purification.....q.s. to 1 ml \n以下空白

• 關聯藥證數量: 1

Polyhexamethylene biguanide hydrochloride

• 關聯藥證數量: 1

Polyhexamethylene biguanide, PHMB

• 關聯藥證數量: 1

Polyhexamethylene biquanide (PHMB).....0.0015 mg/ml;\nEdetate. 2Na.....0.5 mg/ml;\nPoloxamer.....2.0 mg/ml; \nPovidone K30.....0.118 mg/ml;\nBoric acid.....6.4 mg/ml;\nBorax.....0.9 mg/ml;\nSodium chloride.....6.0 mg/ml;\nPurified Water.....q.s. to 1 ml; \n以下空白

• 關聯藥證數量: 1

Polyhexamthylene biguanide(PHMB).....0.0018mg/ml\nBoric acid.....6.4mg/ml\nSodium borate.....0.9mg/ml\nSodium chloride.....6mg/ml\nEdetate.2Na.....0.5mg/ml\nPoloxamer.....1mg/ml\nHPMC.....0.7mg/ml\nWater for purification.....q.s.to 1ml \n以下空白

• 關聯藥證數量: 1

Polyhexamthylene biquanide (PHMB)..... 0.0015 mg/ml;\nEdetate. 2Na.....0.5 mg/ml;\nPoloxamer.....0.5 mg/ml;\nHPMC..... 1.2 mg/ml;\nBoric acid.....6.4 mg/ml;\nBorax..... 0.9 mg/ml;\nSodium chloride..... 3.6 mg/ml;\nPotassium chloride.....0.4 mg/ml;\nWater for purification..... q.s. to 1 ml\n以下空白

• 關聯藥證數量: 1

Polyhexamthylene biquanide (PHMB).....0.0018 mg/ml;\nEdetate. 2Na.....0.5 mg/ml;\nPoloxamer.....2 mg/ml;\nHPMC.....1.2 mg/ml;\nPropylene glycol.....2.0 mg/ml;\nSodium Hyaluronate.....0.05 mg/ml;\nBoric acid.....15 mg/ml;\nDisodium Hydrogen Phosphate.....0.24 mg/ml;\nSodium chloride.....1.2 mg/ml;\nPotassium chloride.....0.5 mg/ml;\nWater for purification..... q.s. to 1 ml\n以下空白 \n

• 關聯藥證數量: 1

Polyhexanide.....0.001mg\nPoloxamer 188.....1mg\nDisodium Edetate.....0.5mg\nDisodium Phosphate Anhydrous.....1.015mg\nSodium Chloride.....8.75mg\nSodium Dihydrogen Phosphate Dihydrate.....0.38mg\nPurified Water q.s. to.....1ml\n以下空白\n

• 關聯藥證數量: 1

Polymigel (CO-PPT of Al(OH)3：CaCO3：MgCO3=2：2：1) contains 19.5%~24.5% of Al2O3, and 9.5%~14.5% of MgO, and 21.5%~26.5% of CaO, on the dried basis.

• 關聯藥證數量: 1

Polyoxy40

• 關聯藥證數量: 1

Polyoxyethylene Polyoxypropylene Block Copolymer (Poloxamer 407)

• 關聯藥證數量: 1

Polyquaternium-1

• 關聯藥證數量: 1

Polyquaternium-1(Polyquad).....0.01mg;\nAL-6289(N[3-Dimethylamino]propyl) tetradecanamide.....0.006mg+up to 7% excess;\nEOBO-41TM-polyoxyethylene-polyoxybutylene.....0.4mg;\nTetronic 1304 (poloxamine).....0.4mg;\nSorbitol.....12.0mg;\nBoric Acid.....6.0mg;\nSodium citrate.....6.5mg;\nSodium Chloride.....1.0mg;\nDisodium EDTA (edentate disodium).....0.5mg;\nUltra Pure AMP(2-amino-2methyl-1-propanol).....4.2mg;\nSodium hydroxide and/or Hydrochloric acid pH adjust to 7.8;\nPurified water Q.S 以下空白\n\n\n\n\n

• 關聯藥證數量: 1

Polysaccharide Iron Complex is a combination of saccharide and iron. It contains not less than 44.5% and not more than 47.5% of iron.

• 關聯藥證數量: 1

Polystyrene microwell ELISA plate caoted with a purified Ribosome P antigen, (12-1×8 wells). ELISA Negative Control, containing human serum with no human antibodies to Ribosome P.Ribosome P ELISA Low Positive, containing human serum antibodies to Ribosome P.Ribosome P ELISA High Positive, containg human serum antibodies to Ribosome P.HRP Sample Diluent, containing Tris-buffered saline, Tween 20, protein stabilizers.HRP Wash Concentrate, containing Tris-buffered saline and Tween 20. HRP IgG Conjugate, (goat), anti-human IgG, containing buffer, protein stabilizers.TMB Chromogen.HRP Stop Solution, 0.344M Sulfuric Acid.

• 關聯藥證數量: 1

Polystyrene microwell ELISA plate coated with a purified Sm antigen, (12-1x 8 wells)\nELISA Negative Control,containing human serum with no human antibodies to Sm\nSm ELISA Low Positive containing human serum antibodies to Sm\nSm ELISA High Positive containing human serum antibodies to Sm\nHRP Sample Diluent,containing Tris-buffered saline, Tween 20, protein stabilizers\nHRP Wash Concentrate,containing Tris-buffered saline and Tween 20.\nHRP IgG Conjugate,(goat),anti-human IgG,containing buffer, protein stabilizers\nTMB Chromogen\nHRP Stop Solution,0.344M Sulfuric Acid

• 關聯藥證數量: 1

Polystyrene microwell ELISA plate coated with a purified Jo-1 antigen

• 關聯藥證數量: 1

Polystyrene microwell ELISA plate coated with a purified rabbit IgG antigen, (12-1 x 8 wells)\nELISA Negative Control, 1 vial of buffer containing human serum with no human antibodies to RF IgG, prediluted, 1.2mL \nRF IgG ELISA Calibrator A, 1 vial of buffer containing human serum antibodies to RF IgG, prediluted, 1.2mL \nRF IgG ELISA Calibrator B, 1 vial of buffer containing human serum antibodies to RF IgG, prediluted, 1.2mL \nRF IgG ELISA Calibrator C, 1 vial of buffer containing human serum antibodies to RF IgG, prediluted, 1.2mL \n RF IgG ELISA Calibrator D, 1 vial of buffer containing human serum antibodies to RF IgG, prediluted, 1.2mL \n RF IgG ELISA Calibrator E, 1 vial of buffer containing human serum antibodies to RF IgG, prediluted, 1.2mL \n RF IgG ELISA Control, 1 vial of buffer containing human serum antibodies to RF IgG, prediluted, 1.2mL \n HRP Sample Diluent, 1 vial – colored pink containing Tris-buffered saline, Tween 20 \n

• 關聯藥證數量: 1

Polystyrene microwell ELISA plate coated with a purified synthetic CCP IgG antigen, (12-1 x 8 wells), with holder in foil package containing a desiccant\nELISA Negative Control, containing preservative nad human serum with no human antibodies to CCP IgG.\nCCP IgG ELISA Low Positive, containing human serum antibodies to CCP IgG.\nCCP IgG ELISA High Positive/Calibrator A, containing human serum antibodies to CCP IgG.\nCCP IgG ELISA Calibrator B, containing human serum antibodies to CCP IgG.\nCCP IgG ELISA Calibrator C, containing human serum antibodies to CCP IgG.\nCCP IgG ELISA Calibrator D, containing human serum antibodies to CCP IgG.\nCCP IgG ELISA Calibrator E, containing human serum antibodies to CCP IgG.\nHRP Sample Diluent, containing Tris-buffered saline, Tween 20.\nHRP Wash Concentrate, containing Tris-buffered saline and Tween 20.\nHRP IgG Conjugate, (goat), anti-human IgG, containing buffer.\nTMB Chromogen.\nHRP Stop Solution, 0.344M Sulfuric Acid.

• 關聯藥證數量: 1

Pomalidomide contains not less than 98.0% w/w and not more than 102.0% w/w of Pomalidomide [C13H11N3O4], calculated on anhydrous and solvents free basis.

• 關聯藥證數量: 1

Pooled human serum with assigned values in two levels.

• 關聯藥證數量: 1

Pooled plasma from selected,healthy donor,which has been supplemented with a standardized reference D-Dimer preparation.

• 關聯藥證數量: 1

Porbe Reagent \nMycobacterium gordonae. 4x5 tubes\nLysing Reagent \nGlass beads and buffer. 1x20 tubes \n\n

• 關聯藥證數量: 1

Posaconazole (Form- I) contains not less than 98.0% and not more than 102.0% of C37H42F2N8O4, calculated on the dried basis.

• 關聯藥證數量: 1

Positive Control (2.5ml). Purified Cryptococcus neoformans polysaccharide antigen containing a preservative.

• 關聯藥證數量: 1

Positive Control Antigen Suspension\n？Killed L. pneumophila\n？Buffered Saline\n？Sodium Azide**

• 關聯藥證數量: 1

Positive Control-0.7 mL:\nFormaldehyde-inactivated influenza A virus (A/Hong Kong/68 (H3N2) suspension in a buffered protein solution\nNegative Control-0.7 mL:\nBuffered protein solution.\nTest Devices-30 ea.:\nSurface coated with a mixture of anti-influenza A and B antibodies (mouse).\nTransfer Pipettes - 30 ea.\nExtraction Tubes - 30 ea.\nSwabs- 30 ea. :\nSterile Rayon swabs.

• 關聯藥證數量: 1

Positive Control─Inactivated Adenovirus (AD41) in buffer with 0.02% thimerosal as preservative.

• 關聯藥證數量: 1

Positive Control─Sample containing human anti-M. pneumoniae IgM in a buffer containing 0.1% sodium azide.

• 關聯藥證數量: 1

Positive control serum :\nHuman serum containing anti-mannan antibodies, tested negative for anti-HIV1 and HIV2 antibodies, HBs antigen and anti-HCV antibody.\nPreservative: <0.1% sodium azide.

• 關聯藥證數量: 1